These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 28005688)
1. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis. Metz J; Eber E; Resch B Pediatr Infect Dis J; 2017 Jun; 36(6):545-548. PubMed ID: 28005688 [TBL] [Abstract][Full Text] [Related]
2. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. Kua KP; Lee SWH Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192 [TBL] [Abstract][Full Text] [Related]
3. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710 [TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981 [TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era. Resch B; Egger B; Kurath-Koller S; Urlesberger B Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166 [TBL] [Abstract][Full Text] [Related]
7. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Winterstein AG; Eworuke E; Xu D; Schuler P Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089 [TBL] [Abstract][Full Text] [Related]
8. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study. Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513 [TBL] [Abstract][Full Text] [Related]
9. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Robinson KA; Odelola OA; Saldanha I; McKoy N Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098 [TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus (RSV) infection in children with medical complexity. Lim A; Butt ML; Dix J; Elliott L; Paes B Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685 [TBL] [Abstract][Full Text] [Related]
11. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Sánchez-Solis M; Gartner S; Bosch-Gimenez V; Garcia-Marcos L Allergol Immunopathol (Madr); 2015; 43(3):298-303. PubMed ID: 24231153 [TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016). Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL; Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782 [TBL] [Abstract][Full Text] [Related]
13. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. ; Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304 [TBL] [Abstract][Full Text] [Related]
14. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience. Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996 [TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia. Resch B; Liziczai K; Reiterer F; Freidl T; Haim M; Urlesberger B Pediatr Neonatol; 2018 Apr; 59(2):184-188. PubMed ID: 28887119 [TBL] [Abstract][Full Text] [Related]
16. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580 [TBL] [Abstract][Full Text] [Related]
17. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
18. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081 [TBL] [Abstract][Full Text] [Related]